- Open Access
Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats
Genetic Vaccines and Therapyvolume 6, Article number: 9 (2008)
Vectors based on adeno-associated virus-8 (AAV8) have shown efficiency and efficacy for liver-directed gene therapy protocols following intravascular injection, particularly in relation to haemophilia gene therapy. AAV8 has also been proposed for gene therapy targeted at skeletal and cardiac muscle, again via intravascular injection. It is important to assess vector targeting at the level of virion accumulation and transgene expression in multiple species to ascertain potential issues relating to species variation in infectivity profiles.
We used AAV8 vectors expressing human factor IX (FIX) from the liver-specific LP-1 promoter and administered this virus via the intravascular route of injection into 12 week old Wistar Kyoto rats. We assessed FIX levels in serum by ELISA and transgene expression at sacrifice by immunohistochemistry using anti-FIX antibodies. Vector DNA levels in organs we determined by real time PCR.
Administration of 1 × 1011 or 5 × 1011 scAAV8-LP1-hFIX vector particles/rat resulted in efficient production of physiological hFIX levels, respectively in blood assessed 4 weeks post-injection. This was maintained for the 4 month duration of the study. At 4 months we observed liver persistence of vector with minimal non-hepatic distribution.
Our results demonstrate that AAV8 is a robust vector for delivering therapeutic genes into rat liver following intravascular injection.
Adeno-associated viruses (AAV) are attractive vectors for in vivo gene therapy due to their safety profile and ability to achieve long term production of therapeutic genes following cell infection. Intravascular delivery provides a minimally invasive yet versatile approach to gene therapy for applications to correct liver deficiencies or utilise this organ for production of therapeutic genes. AAV serotype 2 (AAV2) has been studied in detail preclinically with success [1–5], however, this vector generates a cytotoxic T-cell response as evidenced in human subjects on a haemophilia trial leading to transient transaminitis and only short term FIX production . Alternate AAV vectors are being pursued for gene therapy to overcome limitations in the efficiency of AAV2-mediated gene delivery to the liver . AAV8 in particular shows promise in this regard since it is less immunogenic than AAV-2 capsids . AAV8 has been shown to have improved liver transduction efficiency in murine models of 10–100 fold increase over AAV2 vectors  and rapid uncoating post-internalisation overcomes additional limitations of AAV2 . A number of studies have already assessed the potential of AAV8 using mouse and non-human primate models for haemophilia gene therapy and application to muscular dystrophy [11–14]. Importantly, it has been demonstrated that peripheral venous administration is as effective as the direct intraportal route of vector administration in animal models suggesting profound liver targeting capacity . In addition, Wang et al demonstrated the long-term efficacy and safety of the AAV2/8 vector in liver-directed gene therapy in dogs . The application of the vector to gene therapy is therefore dictated by the tropism observed following administration by a particular route of administration. Subtle differences between species can have a large impact on efficiency and safety. No studies to date have addressed AAV2/8 biodistribution or transgene expression following iv delivery in rats, a particularly important model for many pre-clinical diseases. This study therefore sought to quantify both parameters following peripheral vein injection into adult male Wistar Kyoto rats. We used an AAV8 pseudotyped self-complementary AAV vector, with the liver-specific enhancer/promoter LP1 driving expression of the reporter gene hFIX [11, 12] and assessed biodistribution, transgene expression and longevity of expression.
Animal procedures were performed in accordance with UK Home Office Animals (Scientific) Procedure Act 1986, UK and Personal Licences regulations. scAAV8-LP1-hFIX vector at doses ranging from 1010vg/rat to 5 × 1011vg/rat were administered to 12 week old Wistar Kyoto rats (n = 3/group) via femoral vein injection.
The construction and production of this vector was described previously . Briefly, scAAV8-LP1-hFIX was constructed using a recombinant AAV2 vector backbone incorporating an expression cassette with the human factor IX gene and driven by a liver-specific enhancer/promoter LP1, and subsequently cross-packaged as a dimer into the AAV8 capsid protein. The scAAV8 pseudotyped vector was produced by the triple transient transfection method and purified by ion exchange chromatography. Vector genome titres were determined by the previously described quantitative slot-blot method using supercoiled plasmid DNA as standards .
Quantitative analysis of vector DNA from tissues of scAAV8-LP1-hFIX infused rats to determine biodistribution profile of rAAV8 vector
Four months after vector infusions animals were sacrificed and tissues immediately snap frozen in liquid nitrogen then stored at -70°C. DNA concentrations were quantified by spectrophotometry and 100 ng of purified DNA from each tissue sample obtained was used in a Sybr Green PCR assay, with 200 nmol/L of sense (5'-TTTCCTGATGTGGACTATGT-3') and 200 nmol/L of anti-sense primer (5'-TCATGGAAGCCAGCACAGAACATG-3'), to quantify vector DNA by TaqMan PCR (Perkin-Elmer, Applied Biosystems, Foster City, California). A human FIX quantification standard curve was generated from 10-fold serial dilutions of scAAV8-LP1-hFIX preparation. Target template serial dilutions and all experimental samples were run in duplicate. The following reaction conditions were used: denaturation, 95°C for 10 minutes; amplification, 95°C for 15s, 60°C for 1 min (40 cycles); dissociation, 95°C for 15s, 60°C for 15s, 95°C for 15s using a 7900HT ABI Prism Sequence Detection System. Data were processed by the SDS 2.1 software package (Perkin-Elmer, Applied Biosystems).
Determination of circulating human factor IX levels in blood plasma of scAAV8-LP1-hFIX infused rats
Blood samples were collected at days 0, 3, 7, 14, 28, 56, 112 days post injection into citrate buffer (9 parts blood: 1 part anti-coagulant) from the saphenous vein by venipuncture, starting prior to vector administration to obtain baseline measurements, throughout the study and then a final bleed by cardiac puncture at 4 months when rats were sacrificed. Citrate buffered blood samples were centrifuged at 2000 g for 15 minutes then the plasma was collected and subsequently assayed by anti-FX ELISA  to measure circulating hFIX activity.
Histological analysis of human FIX expression in livers of scAAV8-LP1-hFIX infused rats
At 4 months after vector infusions pieces of rat liver lobes were fixed for 16 hours in 10% formalin. Formalin fixed, paraffin embedded specimens were sectioned at 6 μm using a microtome (Shandon Finesse 325, Thermo Electron Co.). Heart tissues were also collected and processed in the same way and used as negative controls for human FIX expression. Sections were deparaffinised and rehydrated in an alcohol concentration gradient then endogenous peroxidase activity was quenched by incubating the sections in 0.3% hydrogen peroxide in methanol for 30 minutes. Unmasking of the antigen was performed using Target Retrieval Solution as per the recommendations of the manufacturer (Dako Cytomation Ltd, UK) then sections were blocked in PBS for 30 minutes before proceeding with staining.
Human FIX expression in tissue sections was analysed by immunohistochemistry using a 1:100 dilution (10 μg/ml) of goat anti-human FIX-HRP antibody (Affinity Biologicals). The negative control was goat IgG used at 10 μg/ml and anti-goat IgG HRP conjugated antibody at 1:10000 (Dako Cytomation Ltd, UK). The primary antibody was incubated overnight at 4°C and the secondary antibody was incubated at room temperature for 1 hour. Diaminobenzidine (DAB) chromagen solution (Dako Cytomation Ltd, UK) was used to detect horse radish peroxidase activity (positive staining shows as brown) and cell nuclei were counterstained in haematoxylin. Sections were dehydrated through an ethanol gradient and mounted in Histomount (Invitrogen). Images were captured by a Hitachi HVC2OA camera attached to an Olympus ×40 microscope.
Results and Discussion
We examined the transduction efficiency and biodistribution profile of scAAV8LP1hFIX in 12 week old male Wister Kyoto rats 4 months following a single systemic injection of the vector via the femoral vein at doses of between 1010vg/rat to 5 × 1011vg/rat or saline control (n = 3 rats per group). The tissue distribution (measured by Taqman™ realtime PCR) of the scAAV8-LP1-hFIX virus was strongly restricted to the liver with virtually no detectable virion accumulation in any other organ (Figure 1). This demonstrates a strong hepatic targeting of AAV8 in a dose dependent manner and was evident at all doses tested (Figure 1). Although the liver is clearly the predominant site for virion sequestration, the pattern in rats is modestly different to both mouse and non-human primates [11–13]. In mice significant levels of virion accumulation were detected in kidney and lungs in addition to liver . In monkeys the majority was localised to liver but splenic accumulation was also observed .
To determine the level of transgene expression circulating in the blood following scAAV8 delivery in rats we performed enzyme-linked immunosorbent assay specific for hFIX on plasma samples taken from rats over the course of the experiment (4 months). Human FIX was detectable in the blood within 3 days and continued to rise until reaching peak levels at 4 weeks, with values of approximately 2.9 ± 0.26 μg/ml, 0.7 ± 0.2 μg/ml, 0.3 ± 0.06 μg/ml and 0.03 ± 0.01 μg/ml with administration of 5 × 1011, 1 × 1011, 5 × 1010, and 1 × 1010 vector genomes/rat, respectively (Figure 2). The plasma concentration of hFIX achieved from a single intravenous injection of 5 × 1011 vg/rat scAAV8-LP1-hFIX produced over 40% physiologic level in just 4 weeks. Infusion of lower doses of 1 × 1011 and 5 × 1010vg/rat scAAV8-LP1-hFIX produced moderate increases in circulating transgene expression. The difference in transgene expression between vector doses was highly significant (P < 0.0001, by one-way ANOVA) demonstrating a dose response throughout the dosing regimens employed.
Immunohistochemical staining of the liver after intravenous administration of scAAV8-LP1-hFIX at doses of 1 × 1011 and 5 × 1011 vg/rat showed expression of hFIX in the hepatocytes at 16 weeks that was substantially higher than hFIX expression in the hepatocytes from rats infused with the lower doses of 1 × 1010 and 5 × 1010 vg/rat (Figure 3). A clear gradient in expression is seen with the most efficiently transduced cells around the portal tract (Figure 3), consistent with observations in mice . No expression was seen in the heart of any of the animals by hFIX staining (data not shown), again confirming the hepatic selectivity of this vector construct.
In summary, we have demonstrated herein that AAV8 can be used to mediate long term stable expression of transgene at therapeutic levels in the rat. This study confirms those conducted in other species relating to the strong hepatic tropism of AAV2/8 following peripheral vein injection and underscores the utility of this virus for gene therapy applications targeted to the liver.
Snyder RO, Miao C, Meuse L, Tubb J, Donahue AR, Lin HF, Stafford DW, Patel S, Thompson AR, Nichols T, Read MS, Bellinger DA, Brinkhous KM, Kay MA: Correction of hemonphilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature medicine. 1999, 5: 64-70. 10.1038/13518.
Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA: Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature genetics. 1997, 16: 270-276. 10.1038/ng0797-270.
Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM: Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proceedings of the national academy of sciences, USA. 1999, 96: 3906-3910. 10.1073/pnas.96.7.3906.
Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML, Bellinger D, Nichols TC, Arruda VR, Lothrop CD, High KA: Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002, 99: 2670-2676. 10.1182/blood.V99.8.2670.
Nathwani AC, Davidoff AM, Hanawa H, Hu Y, Hoffer FA, Nikanorov A, Slaughter C, Ng SYC, Junfang Z, Lozier JN, Mandrell TD, Vanin EF, Nienhuis AW: Sustained high-level expression of human factor IX (Hfix) after liver-targeted delivery of recombinant adeno-associated virus encoding the Hfix gene in rhesus macaques. Gene therapy. 2002, 100: 1662-1669.
Manno CS, Arruda VR, Pierce GF, Glader B, Ragni M, Rasko J, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006, advanced online publication:
Nakai H, Thomas CE, Storm TA, Fuess S, Powell S, Wright JF, Kay MA: A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J virol. 2002, 76 (22): 11343-11349. 10.1128/JVI.76.22.11343-11349.2002.
Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, Calcedo R, Sanmiguel J, Desai RA, Chen CS, Johnston J, Grant RL, Gao G, Wilson JM: Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med. 2006, 12 (8): 967-971. 10.1038/nm1445.
Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. PNAS. 2002, 99: 11854 -111859. 10.1073/pnas.182412299.
Thomas CE, Storm TA, Huang Z, Kay MA: Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. Virology. 2004, 78: 3110-3122. 10.1128/JVI.78.6.3110-3122.2004.
Nathwani AC, Gray JT, McIntosh J, Ng CYC, Zhou J, Spence Y, Cochrane M, Gray E, Tuddenham EGD, Davidoff AM: Safe and efficient transduction of the liver after peripheral vein infusion of self complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood %R 101182/blood-2006-03-010181. 2006, blood-2006-03-010181.
Nathwani AC, Gray JT, Ng CYC, Zhou J, Spence Y, Waddington SN, Tuddenham EGD, Kemball-Cook G, McIntosh J, Boon-Spijker M, Mertens K, Davidoff AM: Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood %R 101182/blood-2005-10-4035. 2006, 107 (7): 2653-2661.
Davidoff AM, Gray JT, Ng CYC, Zhang Y, Zhou J, Spence Y, Bakar Y, MNathwani AC: Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Molecular Therapy. 2005, 11 (6): 875-888. 10.1016/j.ymthe.2004.12.022.
Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X: Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nature biotechnology. 2005, 23: 321-328. 10.1038/nbt1073.
Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM, Wilson JM: Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood %R 101182/blood-2004-10-3867. 2005, 105 (8): 3079-3086.
Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, Nienhuis AW: Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood. 2001, 97 (5): 1258-1265. 10.1182/blood.V97.5.1258.
This work was supported by the British Heart Foundation and Medical Research Council. We thank Nicola Britton and other members of the BHF GCRC for assistance with animal experiments.
The author(s) declare that they have no competing interests.
TG performed experiments. LW performed experiments. JM performed the ELISAs and prepared the virus. AN participated in the design of the study and provided virus. AB designed the study and drafted the paper. All authors read and approved the final manuscript